Hospira Recalls Labetalol Hydrochloride Due to Cracked Vials

News
Article

The company is voluntarily recalling three lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL Vial and one lot of Labetalol Hydrochloride Injection, USP, Novaplus because of the potential of cracked glass at the rim of the vials.

On Feb. 23, 2018, Hospira, a Pfizer company, announced it was voluntarily recalling three lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL Vial (NDC 0409-2267-20), and one lot of Labetalol Hydrochloride Injection, USP, Novaplus (NDC 0409-2267-25) to the hospital/institution level. The company is recalling the lots because cracks were found on the rim surface of their vials, which could result in a lack of sterility.

The potential lack of sterility assurance posed by the cracked rim surfaces of the vials may result in the use of or exposure to non-sterile product, which could cause fever, chills, sepsis, or invasive systemic infections in patients. As of February 23, the company had not received any reports of adverse events related to the recalled lots.

According to Hospira, Labetalol Hydrochloride is “an adrenergic receptor-blocking agent indicated for the control of blood pressure (BP) in severe hypertension. It is administered by repeated intravenous (IV) injections or by slow IV infusion.”

The recalled lots were distributed nationwide to wholesalers, retailers, and hospitals in the United States and Puerto Rico from April 2017–August 2017. The company is advising customers to stop use and distribution of any remaining units. Adverse events may be reported to FDA via its MedWatch program.

Source: FDA

 

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.